Title: MOLECULAR MODIFICATIONS Special Processes
1MOLECULAR MODIFICATIONSSpecial Processes
Ring closure, opening, or variation
- ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Formation of higher or lower homologs
Introduction of double bonds
2MOLECULAR MODIFICATIONSSpecial Processes
Introduction of stereogenic centres
- ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Introduction, removal, replacement of bulky groups
3ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Ring Closure, Opening, Variation
- Physostigmine, Neostigmine, Pyridostigmine
- Chlorpromazine, Prochlorperazine, Thioridazine
- Amphetamine, Tranylcypromine
4 RING CLOSURE
Prochlorperazine
Chlorpromazine
Thioridazine
5 RING OPENING
Dicumarol
Amphetamine
Warfarin
Tranylcypromine
6 RING VARIATIONS
Clemizole
Tripelennamine
Cyclizine
Antazoline
7 RING VARIATIONS
Parathiazine
Clobenzepam
8ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Formation of Higher or Lower Homologs
- Regular increase in activity
9ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Introduction of Double Bonds
- Stereochemical implications
cortisone
prednisolone
10ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Introduction of Stereogenic Centres
- terbutaline - gt 30001 trachea
relaxation
- flecainide -
antiarrhythmic
- tranylcypromine gt - 21 MAO
inhibition
- arylpropionic acids S gt R
antiinflammatory
11ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Introduction, Removal, Replacement of Bulky Groups
1.
Agonists Antagonists
2.
Change in relative activity
12ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Agonists Antagonists
acetylcholine
tridihexethyl
propranolol
noradrenaline
13ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Agonists Antagonists
serotonin
methysergide
14ALTERATIONS WHICH CHANGE MOLECULAR DIMENSIONS
FLEXIBILITY
Change in relative activity
benzylpenicillin
(lactamase labile)
methicillin
(lactamase stable)